Journal ArticleOPEN ACCESS

Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?

  • Adderley H
  • Ackermann C
  • Califano R
Annals of Translational Medicine (2019) 7(S8) S346-S346
DOI: 10.21037/atm.2019.09.116
N/ACitations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

EGFR tyrosine kinase inhibitors (TKIs) represent the standard of care for first-line treatment for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC) with superiority in overall response rate (ORR), progression free survival (PFS) and quality of life …

Cite

CITATION STYLE

APA

Adderley, H., Ackermann, C. J., & Califano, R. (2019). Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line? Annals of Translational Medicine, 7(S8), S346–S346. https://doi.org/10.21037/atm.2019.09.116

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free